CCM
Camber Capital Management Portfolio holdings
AUM
$718M
This Quarter Return
-0.95%
1 Year Return
-4.23%
3 Year Return
+26.63%
5 Year Return
+47.71%
10 Year Return
+121.3%
AUM
$2.59B
AUM Growth
+$2.59B
(-3.6%)
Cap. Flow
-$10M
Cap. Flow
% of AUM
-0.39%
Top 10 Holdings %
Top 10 Hldgs %
61.39%
Holding
42
New
6
Increased
10
Reduced
14
Closed
4
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$98.8M |
| 2 |
Gilead Sciences
GILD
|
$83.5M |
| 3 |
Merck
MRK
|
$76.6M |
| 4 |
Incyte
INCY
|
$66.1M |
| 5 |
Viatris
VTRS
|
$54.1M |
Top Sells
| 1 |
Tenet Healthcare
THC
|
$127M |
| 2 |
HCA Healthcare
HCA
|
$109M |
| 3 |
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
|
$68.9M |
| 4 |
Ionis Pharmaceuticals
IONS
|
$33.8M |
| 5 |
Alkermes
ALKS
|
$33.1M |
Sector Composition
| 1 | Healthcare | 96.7% |
| 2 | Technology | 3.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Viatris
VTRS
$12.3B
| $216M | 7.44% | 16,000,000 +4,000,000 | +33% | +$54.1M |
|
2
Universal Health Services
UHS
$11.6B
| $214M | 7.35% | 1,650,000 +200,000 | +14% | +$25.9M |
|
|
3
Merck
MRK
$210B
| $192M | 6.58% | 2,500,000 +1,000,000 | +67% | +$76.6M |
|
4
Sanofi
SNY
$121B
| $190M | 6.54% | 3,800,000 +800,000 | +27% | +$40.1M |
|
|
WBA
5
DELISTED
Walgreens Boots Alliance
WBA
| $183M | 6.27% | 3,500,000 -500,000 | -13% | -$26.1M |
|
|
6
Gilead Sciences
GILD
$140B
| $163M | 5.61% | 2,250,000 +1,150,000 | +105% | +$83.5M |
|
7
Zimmer Biomet
ZBH
$21B
| $127M | 4.37% | 1,000,000 +274,910 | +38% | +$34.9M |
|
8
GSK
GSK
$79.9B
| $110M | 3.79% | 2,500,000 -250,000 | -9% | -$11M |
|
|
9
Vertex Pharmaceuticals
VRTX
$100B
| $98.8M | 3.4% | +450,000 | New | +$98.8M |
|
|
10
Tenet Healthcare
THC
$16.3B
| $98M | 3.37% | 1,200,000 -1,550,000 | -56% | -$127M |
|
11
BioMarin Pharmaceuticals
BMRN
$11.2B
| $89.7M | 3.08% | 1,015,000 -135,000 | -12% | -$11.9M |
|
|
CHNG
12
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $85.5M | 2.94% | 4,000,000 | – | – |
|
|
MRTX
13
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $84.3M | 2.9% | 575,000 +125,000 | +28% | +$18.3M |
|
14
Brookdale Senior Living
BKD
$1.83B
| $82.6M | 2.84% | 16,000,000 | – | – |
|
15
Myriad Genetics
MYGN
$593M
| $75.9M | 2.61% | 2,750,000 | – | – |
|
16
Sarepta Therapeutics
SRPT
$1.78B
| $74.3M | 2.55% | 825,000 +325,000 | +65% | +$29.3M |
|
17
Perrigo
PRGO
$3.27B
| $67.1M | 2.31% | 1,725,000 -775,000 | -31% | -$30.1M |
|
|
18
Incyte
INCY
$16.5B
| $66.1M | 2.27% | +900,000 | New | +$66.1M |
|
19
Biogen
BIIB
$19.4B
| $60M | 2.06% | 250,000 +175,000 | +233% | +$42M |
|
20
Nektar Therapeutics
NKTR
$568M
| $50.7M | 1.74% | 3,750,000 | – | – |
|
|
21
Ionis Pharmaceuticals
IONS
$6.79B
| $42.3M | 1.45% | 1,390,000 -1,110,000 | -44% | -$33.8M |
|
22
OraSure Technologies
OSUR
$242M
| $36.9M | 1.27% | 4,250,000 | – | – |
|
23
Ironwood Pharmaceuticals
IRWD
$214M
| $35M | 1.2% | 3,000,000 -2,500,000 | -45% | -$29.2M |
|
|
24
Alkermes
ALKS
$4.78B
| $30.2M | 1.04% | 1,300,000 -1,425,000 | -52% | -$33.1M |
|
25
PTC Therapeutics
PTCT
$3.92B
| $29.9M | 1.03% | 750,000 | – | – |
|